HealthcareServices

Carcinoid Tumor Industry Overview 2025: Growth Projections and Market Trends

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Carcinoid Tumor Market Size During 2025–2029?

The carcinoid tumor market has experienced significant expansion in recent years. Its valuation is projected to rise from $1.61 billion in 2024 to $1.77 billion in 2025, at a compound annual growth rate (CAGR) of 10.4%. This historical growth can be primarily attributed to the increasing occurrence of neuroendocrine tumors, enhanced public awareness concerning rare cancers, advancements in healthcare infrastructure, the availability of targeted therapeutic options, and the proliferation of clinical trials for innovative treatment methods.

The carcinoid tumor market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $2.62 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.3%. The expansion during this period stems from factors such as an increasing demand for personalized medicine, a heightened emphasis on early detection and accurate diagnosis, the growing acceptance of minimally invasive surgical procedures, broadening research into innovative therapies, and the more widespread application of molecularly targeted treatments. Key trends expected over the forecast horizon encompass the incorporation of AI and machine learning into diagnostic processes, a move towards multi-drug combination therapies, the expansion of telemedicine and remote patient monitoring, an emphasis on patient-focused care approaches, and increased collaborative research efforts.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp

Which Industry Drivers Are Expected To Accelerate The Carcinoid Tumor Market From 2025 To 2029?

The expansion of the obese population is anticipated to drive the progress of the carcinoid tumor market in the future. This demographic consists of people with a body mass index (BMI) of 30 or above, signifying an unhealthy level of body fat. The increase in obesity is linked to elements like inadequate nutrition, insufficient physical exercise, inactive routines, and a rise in the intake of processed, high-calorie food items. Obesity plays a role in the formation of carcinoid tumors through fostering persistent inflammation, insulin insensitivity, and higher levels of growth factor production, which aid tumor expansion. An example demonstrating this trend is data from September 2023 by the Centers for Disease Control and Prevention, a US-based government agency, showing that in 2022, 22 states recorded an adult obesity rate of 35% or greater, an increase from 19 states in 2021. Consequently, the expanding obese population is fueling the development of the carcinoid tumor market.

How Is The Carcinoid Tumor Market Segmented?

The carcinoid tumormarket covered in this report is segmented –

1) By Disease Type: Gastrointestinal Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Lung Neuroendocrine Tumor; Other Disease Types

2) By Treatment: Octreotide; Lanreotide; Telotristat ethyl; Capecitabine (Xeloda); 5-Fluorouracil (5-FU); Doxorubicin (Adriamycin); Etoposide (VP-16); Dacarbazine (DTIC); Streptozocin; Other Treatments

3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

4) By Distribution Channel: Online Channel; Offline Channel

5) By End User: Hospital And Clinics; Academic Institutions; Research Organizations

Subsegments:

1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors; Appendiceal Neuroendocrine Tumors

2) By Pancreatic Neuroendocrine Tumor: Insulinoma; Non-insulinoma; Glucagonoma

3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors; Atypical Carcinoid Tumors

4) By Other Disease Types: Thymic Neuroendocrine Tumors; Ovarian Neuroendocrine Tumors

What Are The Latest Industry Trends Transforming The Carcinoid Tumor Market?

Companies involved in the carcinoid tumor market are increasingly focusing on innovations in diagnostic technologies, such as the fully automated chromogranin A test, aiming to improve early detection and patient outcomes. An automated chromogranin A (CgA) test is an advanced diagnostic instrument designed to quantify chromogranin A levels, a biomarker frequently linked to neuroendocrine tumors, including carcinoid tumors. As an illustration, in October 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, secured FDA clearance for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This achievement represents the first FDA-approved Chromogranin A (CgA) test and stands as the only automated immunoassay globally available for tracking tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. Engineered to measure CgA concentration in human serum, this assay empowers laboratories and cancer centers to monitor tumor development and evaluate the effectiveness of treatments. By substituting manual laboratory-developed tests, it enhances laboratory operational efficiency and facilitates more straightforward interpretation of results. The test functions on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, employing TRACE technology to provide accurate results within under 30 minutes.

Who Are The Key Multinational Companies Dominating The Carcinoid Tumor Market?

Major companies operating in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., Dauntless Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report

Which Region Currently Holds The Largest Share Of The Carcinoid Tumor Market?

North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Carcinoid Tumor Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21127&type=smp

Browse Through More Reports Similar to the Global Carcinoid Tumor Market 2025, By The Business Research Company

Cancer Tumor Profiling Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Circulating Tumor Cells Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795